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To determine whether differences exist in biochemical disease-free survival 
(BDFS) and acute toxicity between African-American (AA) and non-Latino white 
(NLW) men with prostate cancer treated with intensity modulated radiation therapy 
(IMRT). 
Methods and Materials 
Between January 2000 and January 2008, 129 AA and 591 NLW men with 
clinically localized prostate cancer were treated with IMRT.  Median follow up was 26.6 
months for both groups. Kaplan-Meier analysis was used to compute rates of biochemical 
disease free survival.  Chi-square analysis was used to compute rates of acute toxicity.   
Results 
No difference was found in three year biochemical disease free survival (BDFS) 
rates between AA vs. NLW men, p= 0.71. Three year BDFS rates were 92% for NLW 
men vs. 89% for AA men.  Multivariate analysis showed that race was not an important 
predictor of BDFS (p=0.88), while the variables PSA (p=0.003) and Gleason score 
(p=0.01) were.  AA men had a significantly lower rate of gastrointestinal (GI) toxicity of 
grade 2 than NLW men (p=0.014), 6% vs. 13%, respectively.  
Conclusions 
Our study shows no difference in BDFS rates between AA and NLW men treated 
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Prostate cancer is the most common cancer in men and is the second-leading 
cause of cancer death for men in the United States after lung cancer (1). African-
American men have the highest reported incidence and mortality from prostate cancer in 
the world (2). Although African-American men are less likely to participate in prostate 
cancer screening, they are diagnosed at greater frequency, at younger ages, with higher 
prostate specific antigen (PSA) levels, and with a higher grade of disease (2).  
 Radical prostatectomy is an excellent treatment for young, healthy patients with 
disease of favorable prognosis (1). For older patients with favorable prognosis, non-
surgical options are often used, as they offer similar 5-year biochemical disease free 
survival when compared to prostatectomy. Many patients with poor prognosis are treated 
with three-dimensional conformal radiotherapy (3DCRT) or intensity modulated external 
beam radiotherapy (IMRT) in conjunction with adjuvant hormone therapy (3,4). The 
development of IMRT has allowed more precise dosimetry and thus smaller planning 
target volumes and margins.  This has allowed sparing of normal tissue of the rectum and 
bladder, reducing toxicity and morbidity, but allowing for safe dose escalation (5). 
 Black men presenting with earlier clinical stage and treated with radical 
prostatectomy have been shown to be at slightly increased risk for biochemical disease 
recurrence and have higher initial PSA values (3). Several studies suggest a genetic 
difference in prostate cancer that occur in African-American men in the density and 
affinity of androgen receptors, in addition to higher testosterone levels (3). Several large 
clinical studies have reported significantly lower biochemical disease free survival rates 
in African Americans with early prostate cancer treated with surgery compared with non-
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Latino whites treated with surgery (6,7). Whether black men are at increased risk of 
developing gastrointestinal and genitourinary complications has yet to be fully explored 
and determined.  At least one large study found an increase in GU complications in AA 
men treated with implant compared with non-Latino whites (8). We examined BDFS and 
acute GI and GU complications in AA and NLW men in a large cohort of consecutively 



















Statement of Purpose Specific Hypothesis and Specific Aims of the Thesis 
The primary aim of this thesis is to determine whether differences exist between 
African-American men and non-Latino white men with prostate cancer treated with 
intensity modulated radiation therapy with respect to biochemical disease-free survival 
and acute gastrointestinal and genitourinary toxicity.  We predict that African-American 
men will have lower biochemical disease-free survival and higher rates of acute toxicity 


















Methods and Materials 
Data Collection 
After approval from the Yale Human Investigational Committee, clinical 
information from all patients undergoing prostate IMRT administered by the Yale 
Department of Therapeutic Radiology at the Yale New Haven Hospital- Hunter Radiation 
Therapy Center (New Haven, CT) and Lawrence and Memorial Hospital Department of 
Radiation Oncology (New London, CT) from January 2000 through January 2008 was 
resptrospectively collected using the TrialDB Clinical Study Data Management System 
(9). Clinical information including diagnostic and prognostic information, tumor stage, 
all recorded PSA values, Gleason score, risk group, and patient and physician reported 
toxicity information were abstracted by a research assistant (AM). Any reported toxicity, 
regardless of whether it was due to a preexisting condition, was recorded using the 
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 
Version 3.0 guidelines (10).   
Patient Characteristics 
From 1/1/2000 to 1/1/2008, 742 consecutive patients with localized prostate 
cancer were treated with external beam radiotherapy.  Race was classified by self-
identification.  Individuals self-identified as Latino (n=11), Asian (n=9), or Not Specified 
(n=2) were not considered for analysis.  Of the AA and NLW men, 22 were excluded 
because of incomplete follow up.  Therefore, 720 patients were available for BDFS 
analysis and the characteristics of these patients are listed on Table 1.  38 patients of the 
720 patients were excluded in the acute toxicity analysis because of incomplete toxicity 
information. Median follow up was 26.6 months for AA and 26.6 months for NLW men. 
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For the purposes of this study, risk groups were determined by the National 
Comprehensive Cancer Network Guidelines (11). Groups were defined as follows: low 
risk, Stage<T2a and Gleason score <6, and PSA <10 ng/ml; high risk, stage T3 or 
Gleason >8 or PSA>20 ng/ml; intermediate-risk, all others.  
 
Table 1: Patient Characteristics 
 





Age   <0.001 
<65 168 (28%) 65 (50%)  
>65 423 (72%) 64 (50%)  
Clinical Stage   0.06 
T1-T2a 454 (77%) 111 (86%)  
T2b-T2c 71 (12%) 8 (6%)  
T3a-T3b 66 (11%) 10 (8%)  
Gleason Score   0.46 
<6 213 (36%) 54 (42%)  
7 260 (44%) 52 (40%)  
>8 118 (20%) 23 (18%)  
Pretreatment PSA   0.29 
<10 415 (70%) 87 (67%)  
>10 to < 20 121 (21%) 24 (19%)  
>20 55 (9%) 18 (14%)  
MSK Prognosis 
Group 
  0.23 
Favorable  187 (32%) 31 (24%)  
Intermediate 249 (42%) 59 (46%)  
Poor 155 (26%) 39 (30%)  
Hormonal Therapy   0.86 
Yes 137 (23%) 29 (23%)  
No 454 (77%) 100 (77%)  
 
IMRT Technique 
 A standard dose escalated prostate IMRT protocol was institutionally developed 
based on available literature and our own institutional analysis of daily setup error and 
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quality analysis parameters.  All patients underwent 3D CT stimulation and treatment 
planning.  The treating physician contoured the prostate in its entirety.   
 From January 2000 to June 2003, patients were initially treated with 3D 
conformal radiation followed by an IMRT boost.  These patients received 66.6 Gy in 37 
fractions of 1.8 Gy using a 3D conformal technique, followed by a 9 Gy boost (in 5 
fractions of 1.8 Gy) using IMRT.  The 3D conformal radiation was delivered to the 
physician contoured prostate plus a symmetric 1.5 cm margin.  The IMRT boost was 
delivered to the prostate plus a 1.0 cm symmetric margin in all directions, except for a 0.6 
cm posterior margin at the interface of the prostate and rectum. 
 From June 2003 until January 2008, patients undergoing prostate radiation 
(without pelvic radiation) were treated with IMRT through the entire treatment course.  
The planning treatment volume (PTV) was defined as the physician contoured prostate 
plus a symmetric 1.2 cm margin to encompass microscopic extension and prostate 
motion.  The entire seminal vesicles were included at the discretion of the treating 
physician, though routinely the PTV included at least the proximal 1/3 of the seminal 
vesicles.  This PTV was treated to 66.6 Gy in 37 daily fractions as the “primary plan”, 
with dose prescribed to the entire PTV.  As the patients approached the completion of the 
initial 66.6 Gy, they received a second CT treatment simulation, and a prostate “cone 
down” plan was developed based on this second CT stimulation.  The patient then 
underwent 5 additional fractions of 1.8 Gy to a PTV defined as the contoured prostate 
plus a 1.0 cm margin in three dimensions, save for a margin of 0.6 cm at the posterior 
border with the rectum.  There were no scheduled treatment breaks.  Therefore, total dose 
to the prostate was 75.6 Gy in 42 fractions of 1.8 Gy. 
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 An isocentric five-field technique with 18 MV photons was typically used, using 
institutionally standardized normal tissue constraints.  Dmax was constrained to 115% of 
prescribed dose.  Rectal constraint for patients receiving 75.6 Gy was D25 <70 Gy, with 
the 50% isodose line not covering the entire rectum, and the 90% isodose line covering 
half of the rectum width on a slice-by-slice inspection of the entire rectum.  Deviations 
from the standard criteria were allowable when unavoidable and approved by the 
attending physician.  All plans (including both “primary” and “cone down” plans) were 
presented at institutional chart rounds for clinical and dosimetric review.   
Statistical Analysis, Definition of Biochemical Disease Free Survival  
Biochemical disease free survival (BDFS) was calculated using the RTOG-
ASTRO Phoenix Consensus definition of the date of biochemical failure (the date when 
the PSA reaches a level equal to or greater than 2 ng/ml above the post radiotherapy 
nadir) (12).  There was no backdating allowed.  Kaplan-Meir curves for BDFS were 
constructed for each ethnic group and prognostic group and compared with the log-rank 
test.  Univariate and multivariate BDFS analysis was performed using Cox proportional 
hazards analysis. Differences in acute toxicity between ethnic groups were assessed using 
the Chi-square test.  Statistical analysis was performed using SAS version 9.1 (SAS 
Institute Inc, Cary, NC).   
Contributions to Thesis Project  
Steven Oh was at least partially responsible for the conception and design of the 
study, data collection and analysis, and drafting of the manuscript. The study was primary 
designed by Steven Oh, Dr.James Yu, Dr.Ayal Aizer, and Dr.Richard Peschel, the senior 
investigator of the study. The majority of data collection was performed by Anne 
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McKeon, although Steven Oh retrieved a portion of the data used in this study. Data 
analysis was performed by Steven Oh with statistical and software-related assistance 
provided by Dr.Ayal Aizer. The manuscript was prepared by Steven Oh with review and 






















Biochemical disease Free Survival 
Three year BDFS was 89% (76% CI:87-95%) for AA men and 92% (95% CI: 87-
95%) for NLW men. The log-rank test for difference in survival distribution by ethnicity 
was not significant, p= 0.71 (Figure 1).   
 





For the favorable group, three year BDFS was 92% (95% CI:57-99%) for AA men and 
94% (95% CI:83-98%) for NLW men. The log-rank test for difference in survival 
distribution by ethnicity was not significant, p=0.75 (Figure 2).   
 









For the intermediate group, three year BDFS was 88% (95% CI:66-96%) for AA 
men and 90% (95% CI:81-95%) for NLW men. The log-rank test for difference in 
survival distribution by ethnicity was not significant, p=0.95 (Figure 3).   
 









For the poor group, three year BDFS was 87% (95% CI:56-97%) for AA men and 
92% (95% CI:83-96%) for NLW men. The log-rank test for difference in survival 
distribution by ethnicity was not significant, p=0.54 (Figure 4).   
 








In a Cox proportional hazards analysis (Table 2), higher PSA (p=0.003) and 
higher Gleason score (p=0.01) were statistically significant predictors of biochemical 
failure.  Race (p=0.88) was not a statistically significant predictor of biochemical failure.   
 

















































Acute toxicity from IMRT was defined as reported toxicity during or within 60 
days of the end of radiation therapy (Table 3).  GI toxicity of grade 2 was statistically 
lower in AA than NLW men, 6% vs. 13% (p=0.01).  GI toxicity of grade 3 was 1% in 
AA men and 3% in NLW men, and this was not statistically significant (p=0.33). GU 
toxicity of grade 2 was 28% in AA men and 27% in NLW men, and this was not 
statistically significant (p=0.74).  GU toxicity of grade 3 was 7% in AA men and 6% in 
NLW men, and this was not statistically significant (p=0.53).   
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Table 3:  Acute Toxicity 
 
Acute Toxicity  NLW (n=558) AA (n=124) p 
GI Grade 2 75 (13%) 7 (6%) 0.014 
GI Grade 3 14 (3%) 1 (1%) 0.329 
GU Grade 2 148 (27%) 35 (28%) 0.737 























This study demonstrates no difference in biochemical disease free survival 
between African-American and non-Latino white men.  Hispanic patients (n=11) and 
Asian patients (n=9) were excluded from analysis due to small numbers.  In univariate 
and multivariate analysis, black race was not an independent predictor of BDFS among 
patients receiving IMRT.   
 In multivariate analysis, Cohen et al. report that black race predicted shorter 
disease-free survival among surgical patients, but not among radiation patients (6). The 
Cohen study merged data using the Surveillance, Epidemiology, and End Results (SEER) 
database files on 23,353 white patients and 2,814 black patients. This study thus 
comprises a significant number of patients and is far larger than this current series. 
Because this study used Medicare files, only patients greater than 65 years of age were 
included in this analysis. As black men are often diagnosed at a younger age than their 
non-white counterparts, it is possible that this study does not accurately portray the entire 
population given the age constraints. It is possible that there is a significant portion of 
black men who are diagnosed before the age of 65 and would likely have more 
aggressive disease. This raises the possibility that these men would increase the racial 
disparities in outcome and further increase the disease-free survival disparity among 
patients treated with radical prostatectomy. Furthermore, this raises the possibility that 
there could be differences between black and white men treated with radiation. Since this 
study does not include this subset of men diagnosed before the age of 65, it may be 
possible that a difference between these groups does in fact exist. It is important to note 
that the Cohen study pooled data from five SER regions including Atlanta, Connecticut, 
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Detroit, San Francisco, and Seattle. As these represent predominately urban areas, it is 
possible that this subset used for analysis is not representative of other rural areas. Thus, 
the Cohen study may be more of an indication of disparities between urban whites and 
black and not of the trends seen across the United States.  
Several studies have shown that there are no disparities in BDFS for patients with 
localized prostate cancer treated with radiotherapy (13,14,15,16,17).  In the Connell study 
from the University of Chicago, 418 black men and 475 white men were treated with 
conformal radiotherapy between 1988 and 1997. This study found that race was not an 
independent prognostic factor and that conformal radiotherapy was equally effective for 
black and white patients. Of note, this was an older series before the modern IMRT era. 
Despite using older radiation techniques, this series showed no differences between black 
and white men. Our study also finds no difference in three or five year BDFS between 
AA and NLW men. 
Connell notes that black men presented with relatively advanced stages, PSA 
levels, and grades when compared to white men. This supports the notion that higher 
mortality rates in black men are a result of late diagnoses and the associated advanced 
nature of these tumors. Thus, socioeconomic factors such as access and availability to 
health care could be responsible for this difference in presentation. Other explanations for 
this difference include different diets and basal androgen levels. This series also notes 
that different familiar inheritance patterns and genetic variations could affect prostate 
carcinogenesis. Despite a difference at presentation, treatment efficacy was comparable 
for African-American and white men.   
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 On the other hand, Latini et al.  report a large disparity in 3-year actuarial DFS 
rates for prostatectomy patients between AA vs. NLW men, 83% vs. 69% (7). This study 
was also one of the first to include Latino men in the analysis. The Latini study pooled 
the results from the Cancer of the Prostate Strategic Urologic Research Endeavor 
(CaPSURE) database and included 138 Latino men, 608 African-American men and 
5,619 non-Latino white men. Interestingly, this study found that Latino men resembled 
African-American men on sociodemographic characteristics. However, Latinos were 
more similar to non-Latino white men on clinical presentation, treatment, received, and 
disease-free survival. This is of note because much of the literature points to differences 
in socioeconomics as a cause of racial disparities in outcomes. Some argue that 
differences in income and education may be responsible for poorer outcomes in black 
patients. However, the Latini study looked at several sociodemographic factors such as 
education, income, type of insurance, and relationship status. This analysis shows that 
Latino patients are similar to black patients in these sociodemographic factors. Despite 
this, black patients have higher rates of disease recurrence.  
 While some suggest that sociodemographic characteristics are responsible for 
worse outcomes in African-American men receiving surgery, our study finds no disparity 
in BDFS among radiation patients.  This result is encouraging. One possible explanation 
for a lack of disparity in radiation patients treated at Yale is that our referral patterns 
reflect a community population rather than an inner city population.  The city of New 
Haven is 38.8% AA while New Haven county is 12.2% (18). In our study, 18% of the 
patients were AA men and this reflects a community population rather than a true inner 
city population.  It is possible that disparities were not present because AA and NLS were 
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of a similar sociodemographic background.  However, Gondi et al. found an improved 5-
year BDFS in AA versus NLW men with intermediate-risk prostate group in a racially 
diverse university population in New York City (19). Even in an inner city population, 
AA men did not have lower BDFS and in fact had superior 5-year BDFS when treated 
with radiotherapy.  This study confirms the results of Cohen at al. that black race does not 
predict shorter BDFS in radiation patients and the reasons why black race is a predictor 
of shorter BDFS in surgery patients but not radiation patients should be further explored.  
 In order to better understand racial disparities in cancer care, it is helpful to 
consider other disease sites as well. Diffuse large B-cell lymphoma has been shown to 
have different presentations in black versus white patients. In a SEER database study by 
Shenoy et al., the outcomes of 38,522 patients with diffuse large B-cell lymphoma were 
investigated using the Surveillance, Epidemiology, and End Results database from 1992 
to 2007 (20). This database used patients from 13 population-based registries including 
Connecticut, Hawaii, Iowa, New Mexico, Utah, Detroit, San Francisco/Oakland, 
Seattle/Puget Sound, Atlanta, Los Angeles, and San Jose/Monterey.  Like many other 
cancer disease sites, black patients with diffuse large B-cell lymphoma were diagnosed at 
a younger age compared with white patients, 54 versus 65 years, respectively (20).  
Furthermore, a greater proportion of black patients presented with stage III/IV disease 
when compared with white patients, 52% versus 45% (20). 31% of black patients 
presented with B symptoms while 24% of white patients presented with B symptoms 
(20).  Whites had a much higher rate of 5-year relative survival rate as compared to black 
patients, 54% versus 45% (20).  Kaplan-Meir survival curves for diffuse large B-cell 
lymphoma patients demonstrated better survival among whites as compared with blacks.  
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Compared with whites, black patients had a higher mortality, with a hazard ratio of 1.12 
(CI 1.04-1.1) (20). 
A study by Nichols et al. investigated outcomes in black patients with early breast 
cancer treated with breast conservation therapy (21). In this retrospective study, 1231 
consecutive patients greater than 40 years of age and with stage I-II invasive breast 
cancer were treated with lumpectomy and radiation therapy at the University of Chicago 
Hospitals between 1986 and 2004.  34% of patients were black and the remainder were 
Caucasian, Hispanic, or Asian.  Black patients had a poorer 10 year overall survival 
compared with nonblack patients, 64.6% versus 80.8%. In addition, black patients had 
lower disease-free survival compared with nonblack patients, 58.1% versus 75.4%.   
 Nichols discusses that breast cancer mortality has been declining in all women 
since 1990, but the magnitude of this decrease has been greater for white than for black 
patients. Improvements in screening mammography and adjuvant therapy have helped to 
contribute to this decrease in mortality. However, the magnitude of this decrease has been 
a 2.4% yearly decline in Caucasian women versus 1.1% in African-American women. It 
is still unclear why this discrepancy exists. While some have noted that black women 
have been less likely than their Caucasian counterparts to use screening mammograms, 
more recently screening mammograms use has reached the same level in black and white 
women. This makes the underutilization of mammography less likely to explain these 
racial disparities.   
 Of note, this series also states that black patients are more likely to be classified as 
having lower socioeconomic status.  Defining socioeconomic status is difficult and no 
consensus on the most suitable definition has been reached, though many account for 
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marital status, level of education, and income. Despite a lack of a clear consensus, 
Nichols notes that even when controlling for age, stage, and socioeconomic status, race is 
an independent indicator of breast cancer mortality. While many have stated that 
socioeconomic status is a contributing factor to racial disparities in breast cancer 
mortality, it appears that it is not the sole explanation of why these disparities continue to 
persist.  
 Recently, Du et al. performed an analysis using the linked National Longitudinal 
Mortality Study and Surveillance, Epidemiology, and End Results data to determine the 
effects of individual-level socioeconomic factors and racial disparities in receiving 
treatment and in survival. This group used health insurance, education, income, and 
poverty status to qualify individual-level socioeconomic factors. Health insurance was 
further categorized into employer health care, government, Medicare, private company, 
Medicaid, or uninsured. Education was classified into less than high school, high school 
graduate, or some education after high school. Family income was categorized into three 
categories including <$10,000, $10,000 to $34,999, and greater than $35,000. Poverty 
status was measured in terms of the ratio of the family income to the poverty threshold 
for a four person family and grouped into less than 100%, 100% to 400%, and greater 
than 400%.  A total of the eight most common tumor sites were included and consisted of 
breast, colorectal, prostate, lung and bronchus, cervix, ovarian, urinary bladder, and 
melanoma of the skin.  
 Du found that the hazard ratio for cancer-specific mortality was significantly 
higher among black compared with whites (HR, 1.2, 95% CI 1.1-1.3) (22). After further 
controlling for socioeconomic factors and treatment, the hazard ratio was no longer 
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significantly higher for black patients compared with white patients (HR 1.0, 95% CI 0.9-
1.1) (22).  Another interesting finding of this study was that even after controlling for 
socioeconomic factors and patient and tumor characteristics, blacks were significantly 
less likely to receive cancer-directed surgery compared with whites, possibly because of a 
less favorable stage distribution at diagnosis (22).  It is notable that this recent study 
showed that hazard ratios for all-cause and cancer-specific mortality among blacks 
compared with whites for 8 leading tumors combined lost statistical significance after 
adjusting for socioeconomic factors and treatment. However, it is still difficult to 
determine whether socioeconomic factors help explain racial disparities despite this 
study. Given that other studies have shown that even controlling for socioecononmic 
factors does not explain the large gaps in outcomes, it will be still be important to look 
for other causes and explanations.  One possible reason that this study has shown that 
socioeconomic factors can explain disparities is that it carefully categorized and stratified 
individual factors such as health insurance, education, income, and poverty status. It may 
be that creating more complicated models of socioecnomic factors that incorporate more 
variables will explain more of the current disparities in cancer care.   
 A relevant point that Nichols brings up in his discussion is the prevalence of 
comorbid disease. A higher prevalence of comorbid disease along with obesity has been 
mentioned in the literature as a contributing factor in disparities in outcomes. Comorbid 
disease such as diabetes mellitus and cardiovascular disease can lead to an increase in 
mortality. It is possible that the comorbid disease is contributing to decreased overall 
survival and is an independent factor regardless of race or presence of breast cancer. 
However, race is still independently associated with breast cancer mortality when 
 26
controlling for the effects of comorbid disease. While the Nichols series also noted that 
black patients had a higher incidence of comorbid disease, it is important to note that 
comorbid disease was self-reported. This makes it unclear whether some important 
contributors to early mortality were omitted.   
 Perhaps one of the most interesting points brought up in Nichols’ discussion is the 
role of biology with regards to racial differences in breast cancer. Several biological 
differences have been noted in breast carcinogenesis in African-American women. 
Tumors in black women have been noted more often be estrogen receptor and 
progesterone receptor negative. In addition, tumors tend to be of a higher grade and 
mitotic index. Alterations of p53 have also been noted. It is difficult to determine whether 
this in fact a different biological presentation in black women or if this is due to a later 
presentation in black women. It is possible that these biologic differences do indeed 
reflect an inherently more aggressive tumor phenotype.    
 In another series from the University of Chicago, racial disparities were noted for 
endometrial cancer. Connell et al. compared the outcomes of 70 black and 302 white 
women with endometrial carcinoma who underwent primary surgery at the University of 
Chicago Hospitals between 1980 and 1995 (23).  Black women had higher grade tumors, 
less favorable histologic findings, more comorbid illnesses, and lower socioeconomic 
indices.  Black women had worse 5-year disease-free survival than white women, 52.8% 
versus 75.2%. After controlling for pathologic and socioeconomic differences in 
multivariate analysis, race remained a significant prognostic factor.  
 Connell notes that numerous disparities exist between black and white women 
with endometrial cancer. Of note, endometrial carcinoma is diagnosed twice as frequently 
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in white women as in black women, but black women are approximately twice as likely 
to die from this disease (23). The age-adjusted mortality rate of endometrial cancer for 
black women is 6.0 per 100,000 versus 3.3 in white women (23). Several biologic 
differences have been noted and postulated to account for these racial disparities. For 
example, black women have been noted to have higher tumor grades and less favorable 
histologic findings. In the Connell series, black women did have more papillary serous 
tumors as compared to their white counterparts, 17.1% versus 6.6%, respectively. 
Furthermore, grade 3 tumors were nearly twice as frequent in black women versus white 
women, 31.4% versus 16.9%. Grade 1 tumors were in fact twice as frequent in white 
women as black women, 36.4% versus 17.6%.  This series and previous literature note 
that differences in grade are present between these two groups.  Differences have also 
been noted in p53 mutations in black women. Black women more frequently have p53 
mutations than white women. However, it is still unclear whether this demonstrates more 
aggressive tumor biology or if this is a marker of more advanced disease. One of the most 
relevant findings is that despite controlling for biologic factors such as grade and 
unfavorable histologic patterns, race remains an important prognostic factor.  
 The University of Chicago experience clearly demonstrates racial disparities in 
outcomes between black and white women for both breast and endometrial cancer. One 
of the most puzzling pieces to this story is that these racial disparities do not hold true for 
prostate cancer. It is interesting to note that in the same population, prostate cancer is the 
notable exception for differences in outcome. It is unclear why this would be the case 
given that much of the literature shows worse outcomes for blacks with cancer, regardless 
of site.  
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 While black men do present with a different biology compared to their white 
counterparts, notably higher Gleason scores and initial PSA values, race does not appear 
to be an independent prognostic factor.  On the other hand, race continues to be an 
important prognostic factor for breast and endometrial cancer. An explanation for this 
exception remains elusive, though it has clearly been identified in numerous series that 
there are no differences in biochemical disease free survival between black and white 
men.   
 Racial disparities in cancer therapy remains an important area of investigation. In 
the early 1990s, these discrepancies were first identified in the literature. Since this 
disparity has been described, it is interesting to note whether improvements have been 
made after identifying this as an issue. Gross et al. used the SEER database to investigate 
this question. In this study, a cohort of patients was selected using the SEER-Medicare 
database for patients between the ages of 66 to 85 years and who had a primary diagnosis 
of colorectal, breast, lung, or prostate cancer from 1992 through 2002 (24).  For all sites, 
black patients were less likely than white patients to receive therapy for cancer. Of note, 
definitive therapy for early stage prostate cancer was completed less often in black 
patients versus their white counterparts, 72.4% versus 77.2%. Unfortunately, there was 
no decrease in the magnitude of these racial disparities between 1992 and 2002.   
 One of the most pertinent findings in this study was that for all sites considered, 
black patients were less likely to receive cancer therapy. The final sample consisted of 
143,512 patients and the most common cancer type was prostate cancer with over 82,000 
patients analyzed. It is unclear why 5% less black men recieved definitive therapy for 
stage I prostate cancer. One of the most pressing questions from this data is whether this 
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is a result of access to health care or patient preference. Since both groups were offered 
therapy, it is possible that this difference is a result of patient choice. The fact that 5% 
less black patients chose definitive therapy could reflect a decision by black patients to 
not undergo therapy. While some may argue that black patients do not have the same 
access to health care, it is possible that black patients are choosing not to undergo therapy 
for a variety of reasons, including distrust of the medical system. It would be most 
helpful to know the reasons why some of these black patients chose not to receive 
treatment that their white counterparts chose to receive. One area of investigation that 
was not mentioned is whether a significant portion of the black community remains 
hesitant to receive treatment out of distrust of the medical community.  
 Consistent with the University of Chicago experience, the Gross study notes that 
black patients were more likely to reside in areas with lower median income and other 
measures of socioeconomic status. Despite controlling for this using several models, 
access and socioeconomic status did not entirely explain racial disparities in therapy.  
While access and socioeconomic status have been mentioned repeatedly as the culprit for 
racial disparities, these studies demonstrate otherwise. It is unfortunate to note that this 
study showed no improvement in racial disparities in the past ten years, despite 
identifying this as an issue. Despite efforts to increase awareness of racial disparities and 
increase access to health care over the past decade, black patients are still not receiving 
treatment to the same extent as their white counterparts.  
 Now that disparities have been noted in cancer care, what can be done to improve 
the gap that exists between the care that white and black patients receive? Regardless of 
disease, inequity in the delivery of health care leads to much worse outcomes for certain 
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groups, notably ethnic minorities and the poor.  There are numerous barriers that cancer 
patients face such as the demands of work, family responsibilities, and emotional stress 
(25). These barriers are magnified for minorities and low-income patients who have 
limited access to basic necessities such as transportation and affordable childcare (25).  In 
addition to these barriers, other barriers such as culturally specific health beliefs generate 
distrust of the health care system. Neighborhood-based infrastructural deficits associated 
with poverty can manifest in a lack of the basic personal means or social support to 
successfully navigate the complex world of cancer care (25).   
 In the past decade, therapies for cancer care have significantly improved with the 
advent of multimodality therapy. It is interesting to note that this has inevitably led to 
more complicated care that requires more coordination of care. In fact, as new 
technologies and therapies are developed, many at-risk groups are left behind and the gap 
in health care delivery increases. Thus, already disadvantaged patients do not benefit 
from complex treatment innovations that otherwise are improving health outcomes. The 
complexity of care in fact leaves many from lower socioeconomic status groups behind, 
as they are unable to coordinate their own care and find the means of transportation or 
income to initiate and complete their multimodality care.   
 It is important to note that the communities that many African-American patients 
live in are very different from those of their white counterparts. The social infrastructure 
in place can also be a cause of racial disparities. In many black neighborhoods, the 
doctors who provide care often have less training and access to state of the art clinical 
resources. A lack of infrastructure and community for support during illness are key 
factors that may be contributing to the persistence in health care outcomes disparities. 
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 Recently, the National Cancer Institute initiated the Cancer Disparities Research 
Partnership (CDRP) to develop clinical trials and a research infrastructure within 
communities that serve patient populations facing health care disparity (25). 
Traditionally, black patients have not had the same access to clinical trials and thus 
cutting edge cancer treatment as their white counterparts. Furthermore, this grant 
implemented patient-navigator programs to address the fundamental process-of-care 
disconnects and barriers to care that black patients face.  
 The patient-navigator concept was first described by Harold Freeman and 
implemented in Harlem, NY to address community based barriers as well as distrust of 
the medical system. It consists of a culturally and linguistically appropriate individual 
who supports a patient through the process of care. These individuals can provide support 
and more importantly coordination of care. In addition, they are able to explain the 
rationale and benefit of participation in clinical trials. These navigators in the community 
are also able to elucidate barriers and address all of the barriers that are manifestations of 
the infrastructural and societal deficits in the underserved community that increase a 
patient’s likelihood of not complying with treatment and follow-up regimens (25).   
 The initial experience of the CDRP Urban Latino African American Cancer 
Disparity program in South Los Angeles, California has helped identify several barriers 
facing patients. Of note, community based structural deficits such as lack of 
transportation and other financial resources have proved to limit successful and timely 
completion of cancer treatment. This group has also noted that the fear of cancer and the 
morbidity of treatment has limited compliance with care regimens. Interestingly, the 
constraints on caregiver support have also contributed to deficits in care. These patient 
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navigator systems have the potential to greatly enhance patient compliance and thus 
narrow the gap in racial disparities. It is important to realize that for the disadvantaged 
patient, navigating the health care system can be daunting and close to impossible.  
Having a source of support to coordinate multidisciplinary care can be essential for 
completion of therapy.  
 While the patient navigator system is one model to improve outcomes and 
decrease disparities, there are many barriers that prevent it from being successful 
nationwide. Notably, such programs are expensive to hire and train such navigators. A 
randomized clinical trial would likely be necessary in order to demonstrate that black 
patients have improved outcomes in survival with the help of a navigator. This is most 
likely the only scenario that would justify funding for this program throughout the 
country to help eliminate racial disparities in cancer care.   
 Ultimately, disparity is about poverty and the lack of infrastructure to meet the 
needs of disadvantaged patients (25).  Establishing the necessary infrastructure to narrow 
the disparity gap is clearly an important and essential goal of future health care. Yet the 
exact means by which to set up infrastructure remains uncertain. A key factor that is a 
source of current difficulties is the United States health care system. The current system 
is a mix of government insurance and private insurance, as well as no insurance. 
Insurance companies are not motivated by improving quality and decreasing disparities. 
Instead, they seek to limit costs and emphasize cost control.  Setting up the necessary 
infrastructure for the African-American community to help eliminate disparities will 
require a significant investment in capital. Many today point to the large expenses spent 
on American health care, especially relative to the nation’s gross domestic product. Some 
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would consider our current health system to have many areas of unnecessary spending 
and waste. However, members of the disadvantaged community are not the recipients of 
this unnecessary health care service. In fact, they are the ones that often need it the most.  
In the long run, investing in infrastructures necessary to support the health of minority 
communities will not only decrease the gap in cancer outcomes, but it will improve costs 
as well. Efforts at screening and early detection of disease will most likely decrease 
health care spending by treating diseases at earlier stages when less drastic and costly 
interventions are required.  Establishing the infrastructure to promote health in 
communities will also decrease comorbid disease and its associated costs.    
 One of the greatest challenges of cancer care in the coming years will be to 
narrow the gap in outcomes between African-American and white patients. Disparities 
have been documented for over the past decade. While some progress has been made in 
documenting these differences for various sites, the disparities still persist. It will be up to 
future generations of physicians and leaders to close this gap.  
 Despite the persistence in racial disparities between black and white patients with 
cancer, our study as well as others demonstrate that there are in fact no differences in 
overall survival between black and white patients with prostate cancer treated with 
radiation therapy.  Black men are diagnosed at later stages of disease and often with more 
biologically aggressive disease but seem to fare similarly to their white counterparts after 
receiving radiation therapy. This provides hope that disparities are not inevitable and that 
they can be addressed.  
 One question that remains to be answered is why these disparities do not exist for 
black patients treated with radiation, and yet black patients treated with radical 
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prostatectomy fare worse than their white counterparts. It is puzzling that in the same 
racial group and disease site, one modality of treatment would result in racial disparities 
in outcome while the other does not.  If access to health care is indeed a barrier for black 
patients, it would be expected that patients that receive radiation would fare worse than 
those who receive surgery. Radical prostatectomy is a one day procedure requiring 
hospitalization. On the other hand, a course of radiation requires multiple treatments over 
weeks and one would expect that black patients with difficulty accessing health care and 
transportation would miss more treatments or not complete treatment. This seems not be 
the case.    
 No differences in acute GU toxicity of either grade 2 or 3 were found between 
AA and NLW men treated with IMRT.  In contrast, Chen et al. found an increase in GU 
complications in AA men treated with brachytherapy compared with NLW men (8). 
Acute GI toxicity of grade 2 was less in AA men than NLW men, but no differences were 
found in toxicity of grade 3.  It is possible that AA men have lower rates of GI toxicity of 
grade 2 than NLW men.  Another possible explanation is that AA men are underreporting 
GI toxicity to their physicians because they are uncomfortable mentioning this. Once 
more serious complications arise, such as grade 3 toxicity, they may be more open to 
discussing this with their physicians.  Whether there is underreporting of GI toxicity or if 
AA men have lower rates of acute GI toxicity should be further explored.  
 An analysis of acute toxicity is important because quality of life is an important 
consideration in survivorship. Many studies have described racial disparities in overall 
survival and biochemical disease free survival between African-American men and white 
men. However, acute toxicity has not been widely reported prior to this study. It is 
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important to note that acute toxicity influences how patients rate the quality of their life, 
especially immediately after treatment. Because many patients are successfully treated 
and cured with modern therapy for prostate cancer, acute toxicity and side effects remain 
an important issue. As patients have numerous treatment options ranging from radical 
prostatectomy, brachytherapy, radiation therapy, or cryotherapy, it is important to note 
how side effect profiles may differ.  Many patients are survivors for years after therapy 
and judge the success of their therapy often on the side effects they face or are left with.  
Acute and long-term toxicity will ultimately influence a patient’s quality of life and also 
their willingness to recommend their treatment to others.  It is encouraging to note that 
black men do not suffer from increased side effects immediately after therapy. This is 
also in contrast to the Chen study that demonstrated that African-American men suffer 
from increased GU toxicity following brachytherapy (8).  Further studies are warranted to 
determine whether this lack of racial disparity in acute toxicity persists with IMRT in 
other series from other institutions.   
 A major strength of this study is that it is one of the first to report acute toxicity 
differences between NLW and AA men who receive IMRT for prostate cancer.  
Limitations include the weaknesses of any retrospective study, including the fact that 
patients were excluded because of incomplete follow up or missing toxicity information.  
Furthermore, this study represents the results of only a single institution. Work needs to 
be done to explore acute toxicities in patients of other ethnicities as well.  Because of 
small numbers, we excluded Latino and Asian patients from this analysis.   
 In conclusion, our study of biochemical disease-free survival shows no difference 
in outcomes for African-American versus non-Latino white men.  African-American men 
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have a lower rate of acute GI toxicity of grade 2 with no differences in rate of GI toxicity 
of grade 3 or GU toxicity of grade 2 or 3.  Further studies are needed to determine if 
African-American men have a lower rate of acute GI toxicity or if this is due to 
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